Epilepsy Clinical Trial
Official title:
Ketogenic Diet Program for Epilepsy
This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating epilepsy. Two study groups will be comprised of children with epilepsy (0-18 years of age) and whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet.
According to an evidence-based guideline on the diagnosis and management of epilepsy from the
National Institute for Clinical Excellence (2012), the ketogenic diet may be considered as an
adjunctive treatment in children with drug-resistant epilepsy. Vast anecdotal and Class 1
studies have confirmed that the ketogenic diet helps most children with intractable seizures
and cures many. Dietary therapies for epilepsy (e.g., classic ketogenic diet) have been shown
to be highly effective. For example, Lee (P.R.) and Kossoff reported that approximately 50%
of children with drug-resistant epilepsy had a greater than 50% reduction in seizures within
days to months of treatment. In addition, use of the ketogenic diet as a treatment for
epilepsy has been shown to reduce the escalating costs associated managing poorly controlled
seizures (e.g., decrease in outpatient and emergency visits, inpatient hospitalization,
neuroimaging, electro-encephalography, lab testing, and medication use).
If a child's seizures continue after two to three seizure medications have been tried, the
ketogenic diet should be considered. However, many parents still medicate their children well
beyond these guidelines and tolerate seizure frequency because they have no other
alternatives. Given the physical and emotional toll that recurring seizures exact upon these
children/families, the potential for improvement with the ketogenic diet is substantial.
However, the ketogenic diet remains unavailable to most children.
Approximately 1% of Hawaii's children are projected to have epilepsy, but there is no
established, ketogenic diet program for them to receive this dietary intervention, which can
incorporate culturally distinct foods to improve palatability and compliance. Although the
ketogenic diet has shown promise for broadening the scope of therapeutic options for children
with epilepsy, it requires further study in an ethnically diverse population. At Shriners
Hospitals for Children-Honolulu, the investigators have initiated a ketogenic and related
dietary (e.g., modified Atkins diet) intervention program for children with epilepsy and
started to assess its efficacy in treating epilepsy/seizures. This program also includes
educational seminars and services to patients residing on the other Hawaii islands through
outreach trips. The investigators have begun to enroll children with epilepsy into two groups
based on whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and
epilepsy/non-ketogenic diet; total estimate of 15-30 participants over three years. Based
upon initial findings, the investigators will implement a comprehensive, multidisciplinary
ketogenic diet program that will potentially reach hundreds of children throughout Hawaii,
the Pacific Basin, and elsewhere.
Specific Aims:
Aim 1. To assess the therapeutic efficacy of the ketogenic diet on epilepsy/seizures.
Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly
decreased number and severity of seizures than those that are not on the ketogenic diet,
between baseline to three and six months after the dietary intervention is initiated.
Aim 2. In anticipation of lessened epilepsy/seizures, to determine the (a) change in number
and dose of seizure medications used, (b) change in number of lab tests ordered for epilepsy
management, (c) change in number of emergency room and hospital visits for seizures (or other
neurodevelopmental problems), (d) change in number of neurologic procedures for epilepsy
management (e.g. EEG, MRI, CT), and (e) participant/family satisfaction with the ketogenic
diet.
Hypothesis: The number and/or dosage of medications, lab tests ordered, emergency room or
hospital visits, and neurologic procedures for epilepsy management will decrease, and
participant/family satisfaction will be high for participants who have epilepsy/on the
ketogenic diet than those that are not on the ketogenic diet, between baseline to three and
six months after the dietary intervention is initiated.
Aim 3. To compare differences and/or changes in (a) serum and urine ketone levels and (b)
biochemical profiles as defined from blood and stool (gut or fecal microbiome) specimen
samples.
Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly
higher serum/urine ketone levels and notably different biochemical profiles than those that
are not on the ketogenic diet, between baseline to three and six months after the dietary
intervention is initiated.
Children helped by the ketogenic diet are more likely to reach their highest level of
functioning and become contributing adults. By providing the ketogenic diet as an
intervention therapy for epilepsy in a safe and data-driven manner, the community-at-large
will benefit and medical knowledge concerning dietary treatment for neurodevelopmental
disorders will be advanced.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |